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The coagulation/fibrinolysis system is essential for wound healing after vascular injury. According to the
standard paradigm, the synthesis ofmost coagulation factors is restricted to liver, platelets and endothelium.
We challenged this interpretation by measuring coagulation factors in nine human primary cell types. FX
mRNA was expressed by fibroblasts, visceral preadipocytes/adipocytes and hepatocytes, but not in
macrophages or other cells. All cells expressed FVIII except endothelial cells. Fibroblasts, endothelial cells
and macrophages produced thrombomodulin but not FV. Interestingly, vascular-related cells (platelets/
monocytes) that expressed FV did not express FX and vice versa. Monocytes expressed FV, FVIII and
FXIIIA, which are positive regulators of clot formation, but these cells also contained thrombomodulin, a
negative regulator of coagulation. Our data show that the expression of coagulation factors is much more
complex than previously thought, and we speculate that this intricate regulation of coagulation factor
expression is necessary for correct fine-tuning of fibrinogenesis versus fibrinolysis.
A
therothrombosis is a precursor of atherosclerotic plaque formation and is thus involved in a major cause
of death worldwide1. The capacity of the coagulation system to repair blood vessel damage provoked by
loss of vascular integrity (e.g., trauma or oxidized LDL2, as shown in Figure 1) is critically dependent on
the presence of coagulation factors. This dependence is emphasized by the serious health problems observed in
patients suffering from the congenital absence of such factors and modulators (e.g., thrombomodulin (TM) or
protein C), which normally ensure rapid and appropriate fibrin clot formation or lysis. Upon vascular injury,
tissue factor (TF) expressed from the damaged vasculature and TF-bearing cells, such as monocytes, activate the
initiation phase3 of the coagulation pathway by forming a complex with circulating factor VIIa (FVIIa)4, resulting
in the activation of factor X (FX) (See Figure 1 for an illustration of the vascular endothelial cell layers, including
coagulation factors and cells, and a summary of the results of this paper). In addition, FVIII is an important
cofactor that plays an unambiguous role in the activation of FX in the tenase complex (FIXa, FVIII and FX)5–7. In
addition, the prothrombinase complex, which mediates coagulation through fibrinogenesis, requires FV as a
cofactor. Knowledge of the mechanisms governing coagulation factor synthesis would be valuable for under-
standing atherosclerotic disease and other disorders involving aberrant coagulation.
The liver and platelets are two major sites of FV synthesis, and the liver is a major site of FX production1,4,7–9.
However, FX and FV have been detected in other cells, suggesting that apart from the liver, other cell types
contribute to its expression10,11. This possibility has not been explored systematically. Moreover, although
numerous studies show that FVIII forms a complex with vonWillebrand factor (vWF) released from endothelial
cells, no studies have been conducted to determine whether other circulating cells, such as platelets and mono-
cytes, express FVIII. The absence of such studies seriously limits our ability to obtain a comprehensive under-
standing of how coagulation factor production is regulated.
During the inflammatory reaction following bacterial infection or tissue damage, the activation of coagulation
and the formation of fibrin, which is the final event in the coagulation cascade, represent a defense mechanism
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inflammation and of fibrin formation are completely different, these
processes are closely linked: inflammation induces the coagulation
cascade, while coagulation modifies the inflammation state or
restrains inflammation after completion of wound healing. Coagu-
lation is thus required after inflammation to eliminate the infection,
as was postulated byMackman4. Thus, because defects in coagulation
lead to complications in many inflammatory conditions, knowledge
of the regulatory mechanisms of coagulation factor production is of
major importance for our understanding of vascular disease, cancer
and other pathologies.
In general, the prevailing view is that coagulation factor produc-
tion is restricted to three compartments: the liver, where most coagu-
lation factor production takes place; the endothelium, which is
characterized, for example, by high levels of vWF; and the platelets,
which, despite being devoid of a nucleus, seem to be capable of
substantial coagulation factor production12. However, there is reason
to doubt this view of coagulation factor synthesis. For instance, in the
lung, alveolar macrophages express FVIIa13, while epithelial cells
express TF14, FVIIa15, and Xa10, and fibroblasts express tissue factor
pathway inhibitor16. Similarly, in atherosclerosis, coagulation factors
are synthesized in the atheroma. No systematic investigation of the
capacity of other cell types to produce coagulation factors has been
reported. Hence, we decided to apply ultrapure human primary cell
cultures to assess coagulation factor production. We opted for vas-
cular related cells like endothelial cells (ECs), fibroblasts, macro-
phages, monocytes, bone marrow derived hematopoietic stem cells
and platelets as these cells are important for thrombus formation
under pathophysiological conditions. Moreover, we studied preadi-
pocytes and adipocytes as these cells are tightly linked with obesitas,
which in turn correlates with an increased risk of venous throm-
bosis17,18. Finally, hepatocytes were included as these cells are the best
characterized cells for coagulation factor synthesis.
Results
To investigate whether human cells besides the major sites of coagu-
lation factor production express clotting factors(s), FV mRNA
expression was measured. As depicted in Figure 2A, FV mRNA
was expressed at high levels in human monocytes and hepatocytes,
with hepatocytes, the traditional major site of FV expression, serving
as a positive control. Remarkably, FV was not detected in other cells,
including human macrophages, which are derived from monocytes
Figure 1 | General structure of blood vessels and the factors involved in coagulation. The layers above the lumen show an intact blood vessel, while those
below the lumen show a blood vessel after injury. The blood vessel is divided into four major sections: 1) tunica adventitia, 2) tunica media, 3) tunica
intima and 4) lumen. The tunica adventitia is composed of fibroblasts, connective tissue and collagen and is separated from the tunica media by the
external elastic lamina. The tunica media contains fibroblasts, smoothmuscle cells (SMCs), connective tissue and collagen and is isolated from the tunica
intima by the internal elastic lamina. The tunica intima, which is bordered on one side by the tunica media and on the other side by the lumen, contains
endothelial cells, and in the case of new intima, the internal elastic lamina is damaged and therefore their contents leaks into the tunicamedia. In a normal
vascular system, blood cells circulate in a regulated way (includingmonocytes, platelets, and others). After a vascular injury, the wound healing and repair
process will be immediately activated. However, OX-LDL particles are one of the major causes of chronic vascular injury. After a vascular injury, TF is
released by the wound and forms a complex with the activated FVII (FVIIa) present in circulation, as shown by the black arrow at the site of injury
(indicated in the middle of the lumen). At the same time, monocytes and platelets arrive quickly to the site of the injury to stop bleeding and repair the
injury via the direct activation of coagulation cascade components (FV/FVIII). These two cofactors are involved in the optimal activation of FXa. Both
platelets and monocytes ensure the stability of the fibrin network via cross-linking with FXIIIA, which is delivered by these two cell types.
Thrombomodulin (TM) is also expressed by monocytes, macrophages, endothelial cells, and fibroblasts. When monocytes enter the tissue at the site of
injury, they are converted to macrophages (Mw). Macrophages do not express FV or FX, while fibroblasts express FX but not FV.
www.nature.com/scientificreports
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Figure 2 | (A–C) Expression of FV (A), FX (B) and FVIII (C) by eight human primary cell types: stem cells, fibroblasts, endothelial cells, macrophages,
preadipocytes and adipocytes, hepatocytes and monocytes, with and without exposure to LPS. The level of each mRNA was measured in triplicate and
error bars show standard deviations of means for triplicate cultures per condition and is represented as the mean 6 SEM. The p-value obtained from a
paired t-test with a two-tailed test samples (T-test). P , 0.05 is considered statistically significant. (A) shows the expression of the FV gene by human
monocytes (dark-gray bar) and hepatocytes (light-gray bar). Monocytes and hepatocytes were not exposed to LPS. Hepatocytes were used as a positive
control for coagulation factor expression. Human primary hepatocytes die upon exposure to LPS, and monocytes were not exposed to LPS because LPS
treatment results in the differentiation of monocytes into macrophages. mRNA expression is expressed as 2log (logarithm base 2) values on the y-axis.
Relative mRNA intensity was obtained from three measurements and is represented as the mean 6 SEM. (B) shows the expression of the FX gene by
human fibroblasts, preadipocytes, adipocytes and hepatocytes. Gene expression is expressed as 2log values on the y-axis. Relative mRNA intensity was
obtained from triplicate measurements and is represented as themean6 SEM.Hepatocytes served as a positive control for coagulation factor expression.
(C) shows the expression of the FVIII gene by human primary cells. FVIII mRNA expression was expressed as2log values on the y-axis. FVIII mRNA
expression was observed in all cells tested except endothelial cells. Relative mRNA intensity was obtained from three measurements and is represented as
the mean 6 SEM. Hepatocytes served as a positive control for coagulation factor expression.
www.nature.com/scientificreports
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(Figure 2A). Thus, despite its detection in monocytes and hepato-
cytes, the gene is subject to stringent transcriptional regulation.
Because FV is a cofactor for FX proteolytic activity, we were inter-
ested in investigating whether FX expression would resemble that of
FV. As shown in Figure 2B, FX, like FV, was subject to stringent
transcriptional regulation, as it was only expressed in a subset of cell
types. Its expression, however, was markedly different from FV and
was limited to fibroblasts, visceral preadipocytes, and adipocytes,
where its transcription was as strong as in hepatocytes, the standard
site of its synthesis. Thus, despite being parts of the same enzymatic
complex and despite both FV and FX showing expression outside the
traditional locales of their expression, the regulation of these genes is
markedly different.
In addition to FV, FVIII also acts as cofactor to FX. The partially
mutually exclusive expression of FV and FX raises questions as to the
regulation of FVIII. Interestingly, while FV and FX showed restricted
expression, FVIII was more or less ubiquitously expressed. All cell
types examined expressed the gene to a high level, except endothelial
cells, which only contained trace amounts of FVIII (Figure 2C).
vWF forms a complex with FVIII, which stabilizes FVIII. As FVIII
is also a member of the tenase complex, the expression of vWF
was investigated in all nine human primary cell populations. As
shown in Figure 3A, vWF expression was high in endothelial cells.
In addition, mRNA analysis showed that vWF was expressed by
fibroblasts, macrophages, preadipocytes, hepatocytes and mono-
cytes. However, the expression of vWF was inhibited in preadipo-
cytes upon exposure to lipopolysaccharide (LPS) (Figure 3A),
suggesting that inflammatory stimuli inhibit its production in this
cell type.
After analyzing these coagulation factors that activate prothrom-
bin (the inactive form of thrombin), the mRNA expression of
FXIIIA, a fibrin clot stabilizer, and that of thrombomodulin, an
important and potent thrombin cofactor in the anticoagulant path-
way, were studied. As illustrated in Figure 3B, FXIIIA was produced
at a high level by monocyte-derived macrophages, as well as by
monocytes, and was only weakly expressed by hepatocytes. FXIIIA
expression was not detected in other cells (Figure 3B) and is thus
subject to rigorous transcriptional control. The mRNA expression of
thrombomodulin was high in bone marrow-derived stem cells
(Figure 3C). In addition, thrombomodulin was strongly expressed
in endothelial cells, macrophages, monocytes and, to a lesser extent,
fibroblasts; however, similar to FXIIIA expression in macrophages,
thrombomodulin expression was inhibited after exposure of macro-
phages to LPS. No thrombomodulin expression was detected in vis-
ceral preadipocytes, adipocytes, or hepatocytes, again highlighting
the intricate transcriptional control to which the members of the
coagulation cascade are subject.
Finally, we focused on human platelets, which have obvious rel-
evance to the coagulation process but do not lend themselves well to
common technology for expression analysis. Thus, platelets were
screened for the presence or absence of coagulation factors using
mass spectrometry. Platelets were isolated by iodixanol-gradient
centrifugation, and the production of coagulation factors was subse-
quently assessed by LC-MS/MS. Orbitrap LTQ-XL (LC-MS/MS)
analysis detected FV, FXIIIA and vWF in the platelet fraction
(Figure 4, 5 and 6, respectively), further completing the complicated
picture of the sites of coagulation factor expression.
Discussion
The standard view of coagulation factor production holds that the
present of these factors is restricted to three compartments, listed as
follows, in order of importance: the liver, the endothelium and plate-
lets. To investigate whether other cells are also sites of expression of
FV, FVIII, vWF and FX, the mRNA levels of these factors were
investigated in nine human primary cell types before and after expo-
sure to LPS, with the exception of monocytes and hepatocytes, which
were only studied in the absence of LPS exposure. Human hepato-
cytes cannot survive exposure to LPS, and the exposure ofmonocytes
to LPS results in their differentiation into macrophages. LPS was
used to monitor whether the expression of coagulation factors in
these cells is biologically active. Human primary hepatocytes, the
standard site of coagulation factor synthesis, served as a positive
control in our experiments. LC-MS/MS-based proteomic analysis
of a highly purified human platelet population, isolated by iodixa-
nol-gradient centrifugation, was also performed. We observed a
complicated pattern of expression of these factors, which seems to
contrast with the relatively simple scheme depicted in the literature,
in which coagulation factor production is largely restricted to the
liver, with contributions from the platelet fraction and vWF synthesis
in the endothelium.
FV is the most important FX cofactor and is expressed only by
monocytes and hepatocytes. Mutations resulting in the absence or
dysfunction of activated FV (FVa) lead to hemorrhagic disease; con-
versely, mutations resulting in excessive activity of FV are associated
with thrombosis. In particular, the R506Q mutation (also known as
FV Leiden) is associated with thrombophilia and APC resistance and
is a significant clinical problem19. Here, we observed that monocytes
express FV. Hence, a prediction from our observations is that allo-
geneic bone marrow transplantation (fromwhich monocytes origin-
ate) may be a rational treatment for FV deficiency20.
Although the formation of fibrin is crucial during vascular injury,
a rapid response and acute fibrin clot formation are essential for the
prevention of bleeding and for vascular wound healing. Because we
showed that coagulation factor FV is expressed bymonocytes,mono-
cytes can no longer be considered merely a membrane surface for
activated coagulation factors to be primed by tissue factor: mono-
cytes may play a much more active role and may also be directly
involved in FX activation (FXa) via cell-autonomous FV delivery. FV
can be activated by elastase and cathepsin G, which are present in
monocytes21, further stimulating FX activity through FV-dependent
mechanisms.
Interestingly, almost all components of the coagulation cascade
except FV act in plaques to form the prothrombinase complex.
Notably, monocytes and platelets are only circulating cells, which
supply the necessary FV to activate FX and cannot be considered
tissue-resident cells. When monocytes extravasate by crossing the
endothelium, they differentiate into macrophages (tissue cells) and
lose FV expression (Figure 1). Because coagulation factors need to be
released into the blood, the expression of FV by circulating mono-
cytes suggests that an important function of monocytes may be to
maintain FV plasma levels. The possibility thatmonocytes are amain
source of FV in plasma may explain why previous attempts at rec-
tifying genetically aberrant FV expression with liver transplantation
have failed20. This theory suggests that co-transplantation of bone
marrow (which producesmonocytes) could constitute a viable thera-
peutic approach.
Lipids, collagens, calcium and inflammatory cells are well-estab-
lished components of atherosclerotic plaques22. In addition, fibro-
blasts play an important role in wound healing by synthesizing
collagen and extracellularmatrix23. It is intriguing that the expression
of FX is absent in cells that express FV and vice versa (hepatocytes are
not in direct contact with blood vessels). Proteomic analysis of highly
purified platelets from human plasma reveals that FV and vWF are
present in platelets but not FVIII or FX. Intriguingly, bothmonocytes
and platelets produce FV and vWF but not FX. The previously estab-
lished expression of FV and vWF by platelets4,21,24–26 was confirmed
in our study. Monocytes are different from fibroblasts and macro-
phages with respect to the expression of FV and FX, and it is tempting
to suggest that the different localization of monocytes (circulating)
versus fibroblasts and macrophages (present in tissue and matrix) is
functionally relevant, but obviously further experimentation is
necessary to test this notion.
www.nature.com/scientificreports
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Because FXIIIA27–29 plays an unambiguous role in the stabilization
of the fibrin clot during wound healing and because thrombomodu-
lin, an anticoagulant, functions in a complex with thrombin and is
important for the degradation and lysis of fibrin after vascular repair,
cells were also screened for the expression of FXIIIA and thrombo-
modulin. FXIIIA mRNA was expressed by monocytes, and proteo-
mic analysis of highly purified platelets revealed that these cells also
produce FXIIIA protein. The expression of FXIIIA by these two cell
types also suggests thatmonocytes and platelets are involved not only
in priming coagulation but are also involved in the final event of
fibrin stabilization. Indeed, we observed that monocytes and ma-
crophages, but not platelets, express thrombomodulin. Thrombo-
modulin has been observed on the surface of endothelial cells and
monocytes30–33, which is in agreement with our observations. Based
on these data, we suggest that both platelets and monocytes arrive at
the site of injury and synergistically initiate primary hemostasis and,
Figure 3 | (A-C). mRNA expression of vWF, FXIIIA and thrombomodulin in eight human primary cell types treated either with or without LPS. The
level of eachmRNAwasmeasured in triplicate and error bars show standard deviations ofmeans for triplicate cultures per condition and is represented as
the mean 6 SEM. The p-value obtained from a paired t-test with a two-tailed test samples (T-test). P , 0.05 is considered statistically significant. (A)
mRNA expression of vWF in eight different human primary cell types treated with or without LPS. vWFmRNA expression is expressed as 2log values on
the y-axis. vWFmRNA expression was detected in all cells tested, except preadipocytes and adipocytes. The highest level of expression was in endothelial
cells. Relative mRNA intensity was obtained from three measurements. Hepatocytes served as a positive control for coagulation factor expression.
(B) mRNA expression of FXIIIA in eight human primary cell types treated with or without LPS. FXIIIA mRNA expression was synthesized only by
macrophages and monocytes. LPS inhibited mRNA expression in macrophages. FXIIIA mRNA expression is expressed as 2log values on the y-axis.
Relative mRNA intensity was obtained from three measurements. Hepatocytes served as a positive control for coagulation factor expression. (C) mRNA
expression of thrombomodulin (TM) in eight different human primary cells treated with or without LPS. TMmRNA expression was observed in all cells
except hepatocytes, preadipocytes and adipocytes (2log lower than or close to 1). TM mRNA expression was inhibited by LPS. TM mRNA expression is
expressed as 2log values on the y-axis. Hepatocytes served as a positive control for coagulation factor expression.
www.nature.com/scientificreports
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as a final event, stabilize the fibrin clot to prevent bleeding and aid
repair of the wound.
Our data show that coagulation factor production is complex and
that the role of local production in vascular injury of such factorsmay
be larger than previously thought (see Figure 1). Monocytes have a
direct and dual role in coagulation by producing important cofactors
for FX (FV, FVIII and FXIIIA), but additional regulation is provided
through the production of thrombomodulin, which destabilizes
fibrin clots30, impairs platelet function27–33 and activates the anti-
coagulant protein C pathway. Furthermore, the observation that
LPS can regulate coagulation factor production by monocytes shows
that the system is dynamic and responds to local cues, further sup-
porting the hypothesis that regulation of coagulation factor produc-
tion is highly context dependent and much more complex than
thought. A full understanding of the mechanisms involved could
potentially advance our understanding of the atherothrombotic pro-
cess and open novel rational avenues for treatment.
Methods
Nine human primary cell types were used in this study, including human primary
mesenchymal stem cells from bone marrow (hMSC-BM) (PromoCell, Germany),
human primary dermal fibroblasts (PromoCell, Germany), human primary umbilical
vein endothelial cells (HUVECs) (University Medical Center Groningen (UMCG)
endothelial Facility), human primary peripheral blood CD141 monocytes (LONZA,
USA/Belgium), macrophages (monocytes differentiated to macrophages by phorbol-
12-myristate-13-acetate (PMA), PoieticsTM human primary visceral preadipocytes
(LONZA,USA/Belgium), adipocytes (preadipocytes differentiated to adipocytes) and
hepatocytes (Becton &Dickinson (BD) USA/Germany). All cells were kept in culture
until reaching confluence (4-5 days). Then, cells were washed 5 times with FCS-free
medium. The cells were cultured in the presence or absence of LPS (200 ng/ml). Cells
were exposed to LPS for 24 h. Subsequently, total RNA was collected. The mRNA
expression of the prothrombinase complex (FV and FX), tenase complex (FVIII),
FVIII-stabilized protein (vWF), fibrin clot stabilizer (FXIIIA) and thrombomodulin:
thrombin (THR: TM) complex, which activates protein C, was measured in triplicate
for the 16 cell types. Platelet-associated proteins, collected from a highly pure platelet
population isolated by iodixanol-gradient centrifugation, were analyzed by LC-MS/
MS as described by Birschmann et al.34 (two independent isolations and two inde-
pendent LC-MS/MS analyses were performed). Blood was collected from healthy
volunteers after fasting by venipuncture into tubes containing the anticoagulant
EDTA. All healthy volunteers provided informed consent. Subsequently, different
iodixanol concentrations were prepared and layered within 3-ml tubes. The gradients
were then centrifuged. Highly purified platelet fractions were isolated from the tubes
by aspiration through a needle. Subsequently, platelet-associated proteins were
trypsinized at 37uC for 24 h to convert proteins to peptides. After 12 h of incubation,
100 ng of trypsin was added to the fraction to ensure the complete conversion of
proteins into peptides. After washing the peptide fraction through a C18 column, 5 ml
of the purified platelet-associated protein (peptide) fraction was assayed by liquid
chromatography-mass spectrometry/mass spectrometry (LC-MS/MS). LTQ
ORBITRAP-XL (Thermo Fisher, USA/The Netherlands) was used for MS.
Characterization of cells. Human mesenchymal stem cells from bone marrow. Rigid
quality control tests were performed for each lot of mesenchymal stem cells. They
were tested for cell morphology, adherence rate, and viability. Furthermore, they were
characterized by flow-cytometric analysis of a comprehensive panel of markers, e.g.,
PECAM HCAM, CD45, and endoglin. Differentiation performance was guaranteed
up to 10 population doublings (PDs). In addition, all cells were tested for the absence
of HIV-1, HBV, HCV, and microbial contaminants (e.g., fungi, bacteria, and
mycoplasma).
Human primary dermal fibroblasts (HPDFs). Rigid quality control tests were per-
formed for each lot of human primary dermal fibroblasts. They were tested for cell
morphology, adherence rate and cell viability. Immunohistochemical tests for the
fibroblast-specific antigen CD90 were performed for each lot. Growth performance
was tested through multiple passages up to 10 or 15 PDs under culture conditions
without antibiotics and antimycotics. All cells were tested for the absence of HIV-1,
Figure 4 | Proteomic analysis of FV production by platelets. After one-step iodixanol-gradient centrifugation, purified platelet fractions were collected
and subjected to LC-MS/MS (LC-tandemmass spectrometry). The results are displayed graphically with the intensity expressed as the ion count (y-axis)
and plotted against them/z ratio of the ions (x-axis). The precursor ion-scanmass spectrum of the FV tryptic digest resulted in anm/z of 830.62, as shown
in green. TheMS/MS product ion spectrum obtained from the fragmentation of this precursor ion atm/z 832N62with b-ions (red peaks) and y-ions (blue
peaks) corresponds to the sequence MPMGLSTGIISDSQI from the tryptic FV peptide MPMGLSTGIISDSQIK, as shown in the table (inset). Five
peptides matched the FV protein sequence. Each sample was subjected twice to LC-MS/MS.
www.nature.com/scientificreports
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Figure 6 | Proteomic analysis of vWFproduction by platelets. After one-step iodixanol-gradient centrifugation, purified platelet fractions were collected
and subjected to LC-MS/MS (LC-tandemmass spectrometry). The results are displayed graphically with the intensity expressed as the ion count (y-axis)
and plotted against the m/z ratio of the ions (x-axis). The precursor ion-scan mass spectrum of the vWF tryptic digest resulted in an m/z of 573.96, as
shown in green. The MS/MS product ion spectrum obtained from the fragmentation of this precursor ion at m/z 573N96 with b-ions (red peaks) and
y-ions (blue peaks) corresponds to the sequence LSEAEFEVL from the tryptic vWF peptide LSEAEFEVLK, as shown in the table (inset). Six peptides
matched the sequence of vWF. Each sample was subjected twice to LC-MS/MS.
Figure 5 | Proteomic analysis of FXIIIA production by platelets. After one-step iodixanol-gradient centrifugation, purified platelet fractions were
collected and subjected to LC-MS/MS (LC-tandemmass spectrometry). The results are displayed graphically with the intensity expressed as the ion count
(y-axis) and plotted against the m/z ratio of the ions (x-axis). The precursor ion-scan mass spectrum of the FXIIIA tryptic digest resulted in an m/z of
631.79, as shown in green. TheMS/MS product ion spectrumobtained from the fragmentation of this precursor ion atm/z 931N79with b-ions (red peaks)
and y-ions (blue peaks) corresponds to the sequence LALETALMYGA from the tryptic FXIIIA peptide LALETALMYGAK, as shown in the table (inset).
Five peptides matched the protein sequence of FXIIIA. Each sample was subjected twice to LC-MS/MS.
www.nature.com/scientificreports
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HBV, HCV, and microbial contaminants (e.g., fungi, bacteria, and
mycoplasma).
Human primary peripheral blood CD141 monocytes. Monocytes are floating cells.
Lonza human primary CD141 monocytes were isolated from the peripheral blood
of screened, healthy donors. Peripheral blood was collected from the donors using
apheresis. Monocytes were then isolated using positive immunomagnetic selection
directed against CD14. CD14 was expressed on most monocytes but not on other
mononuclear cells in the blood. The purity of the population of cells was confirmed by
flow cytometry detecting CD14 and CD11b. Each donor was tested and found non-
reactive by an FDA-approved method for the presence of HIV-I, hepatitis B virus and
hepatitis C virus.Where these tests were not possible, cell products were tested for the
presence of viral nucleic acid from HIV, hepatitis B virus, and hepatitis C virus. Cells
were then cryopreserved.
Human primary macrophages. In contrast to monocytes, macrophages are attached
cells. PMA is routinely applied to differentiate monocytes into macrophages35–37.
After the confluence of normal human peripheral blood CD141 monocytes were
differentiated to macrophages by stimulation with 100 ng/ml PMA for 48 h. Cell
quality was confirmed by their attachment to tissue-culture plastic. After two days,
the medium with PMA was replaced with FCS-free medium with and without con-
taining LPS for 24 h. Then, the cells were lysed to isolate total RNA.
Human primary visceral preadipocytes. Human primary visceral preadipocytes are
precursor cells isolated from abdominal tissue that develop into adipocytes when fully
differentiated and are characterized by accumulation of intracellular triglycerides in
lipid droplets. The visceral preadipocyte cell system contains human visceral prea-
dipocytes. Cell viability, morphology and proliferative capacity were measured after
recovery from cryopreservation. Visceral pre-adipocytes were characterized mor-
phologically at day 10 using AdipoRedTM. After removing medium and washing the
cells, the cells were incubated with the differentiation medium without serum and
incubated either with or without LPS for 24 h. Then, the cells were lysed to isolate
total RNA.
Human primary visceral adipocytes.Human visceral preadipocytes were differentiated
into adipocytes according to instructions provided by PromoCell. Briefly, human
primary preadipocytes were cultured to confluence in growth medium provided by
PromoCell in 5% CO2 at 37uC. When the cells reached confluence, the growth
medium was removed and replaced with preadipocyte differentiation FCS-free
medium supplemented with 0.5 mM 3-isobutyl-1-methyxanthine, 400 ng/ml dexa-
methasone, 0.5 mg/ml bovine insulin, 9 ng/ml L-thyroxine, 3 mg/ml ciglitazone and 8
mg/ml D-biotin (all from PromoCell) for 72 hours. After 3 days, the differentiation
medium was removed and replaced with adipocyte nutrition medium containing 3%
FCS, 8 mg/ml D-biotin, 0.5 mg/ml bovine insulin, and 400 ng/ml dexamethasone for
16 days (mature adipocytes). After maturation of adipocytes, the nutrition medium
was removed, and the cells were washed 5 times with the FCS-free differentiation
medium without supplement. The cells were then incubated with the differentiation
medium without FCS and supplement and incubated either with or without LPS for
24 h. Then, the cells were washed with PBS 5 times. Finally, the cells were lysed to
isolate total RNA.
Human primary fresh hepatocytes. Human primary fresh hepatocytes maintain their
morphology and function for long-term assays, such as enzyme induction, toxicity,
metabolism of stable compounds, and drug transporter assays. These fresh human
hepatocytes were characterized for phase I and II enzyme activity. All cells were tested
for CYP3A4 activity with a 6b-testosterone hydroxylase assay. BD human primary
fresh hepatocytes were prepared from fresh liver tissue to maintain cell health,
morphology and viability. A BD Matrigel overlay created a more physiological-like
environment.
Human umbilical vein endothelial cells (HUVECs). University Medical Center
Groningen has had an Endothelial Cell Facility since 1995. HUVECs obtained from
the Endothelial Cell Facility of UMCG (The Netherlands)38–41 were isolated from
umbilical cords. The endothelial cells were characterized morphologically by growth
contact inhibition and their typical cobblestone appearance at confluence and by
immunologically using indirect immunofluorescence for intracellular vWF. Cells
were phenotyped by flow cytometry for the presence of the endothelial cell marker
CD31. All cells were cultured at 37uC in a humidified 5% (v/v) CO2/95% air atmo-
sphere.
mRNA expression analysis. Total RNA was collected from human primary cell lysates
before and after LPS treatments using a NucleoSpin RNA II kit (BIOKE) according to
manufacturer’s instructions, including DNase I treatment (BIOKE). RNA quality and
concentration were assessed in a Bioanalyzer (Experion), (Bio-Rad, USA/The
Netherlands) using the Agilent RNA 6000 Nano kit (Agilent, The Netherlands). A
Total RNA Amplification Kit was applied to amplify and label the RNA (Applied
Biosystems, The Netherlands). Total RNA was reverse-transcribed into cDNA, and
the concentrations were determined in NanoDrop as above. cRNA was biotinylated
with an RNA Amplification Kit (Ambion, USA) according to the manufacturer’s
instructions, starting with 200 ng total RNA. Samples were purified using the RNeasy
kit (Qiagen, The Netherlands). Hybridization to the Sentrix Human Expression
BeadChip (Illumina, USA), washing, and scanning were performed according to the
BeadStation 500 manual (revision C). One BeadChip with 12 samples was used. Each
slide was scanned immediately. After the scanning, the following steps were per-
formed: 1: quality check; 2: background correction; 3: normalization to a house-
keeping gene; and 4: utile normalization of the data using Beadstudio Expression
module v 3.2.7.After these 4 steps, a relative mRNA intensity of 4 was considered cut-
off and designed as the threshold level.
This study was approved by the Medical Ethics Committee of the University
Medical Center Groningen with the reference number METc2007.081.
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